id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-291923-jvbehgb7	Rajoli, R. K.	Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis	2020-05-06		.txt	text/plain	4442	286	55	The present study used physiologically-based pharmacokinetic (PBPK) modelling to inform optimal doses of nitazoxanide capable of maintaining plasma and lung tizoxanide exposures above the reported nitazoxanide 90% effective concentration (EC90) against SARS-CoV-2. Methods: A whole-body PBPK model was constructed for oral administration of nitazoxanide and validated against available tizoxanide pharmacokinetic data for healthy individuals receiving single doses between 500 mg SARS-CoV-2 4000 mg with and without food. The model predicted optimal doses of 1200 mg QID, 1600 mg TID, 2900 mg BID in the fasted state and 700 mg QID, 900 mg TID and 1400 mg BID when given with food, to provide tizoxanide plasma and lung concentrations over the reported in vitro EC90 of nitazoxanide against SARS-CoV-2. The model and the reported dosing strategies provide a rational basis for the design (optimising plasma and lung exposures) of future clinical trials of nitazoxanide in the treatment or prevention of SARS-CoV-2 infection.	./cache/cord-291923-jvbehgb7.txt	./txt/cord-291923-jvbehgb7.txt